Chronic Lymphocytic Leukemia

Clonotypic Test Can Find Minimal Residual Disease

Published in Blood Weekly, April 12th, 2001

by Michael Greer, staff medical writer - Researchers in New York have developed an effective test for finding residual disease in chronic lymphocytic leukemia (CLL) patients in remission.

Ariela Noy and colleagues at the Memorial Sloan-Kettering Cancer Center investigated the power and accuracy of a clonotypic polymerase chain reaction (cPCR) assay using oligonucleotides specific to each patient's tumor cells.

Noy et al. found that their screen was both sensitive and specific for finding minimal residual disease (MRD), perhaps even more so than conventional assays.

All 10 patients in either partial remission or nodular partial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-04-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry